3 results about "Hepatitis B virus core Antigen" patented technology

The application discloses a recombinant virus-like nanoparticle for immunotherapy of gastric cancer and application thereof. The recombinant virus-like nanoparticle is a chimeric recombinant virus-like nanoparticle formed by self-assembly of a fusion protein HBC-CLDN18.2 of a hepatitis B virus core protein and CLDN18.2 tight junction protein. The application uses genetic engineering technology to truncate the C-terminal end of a natural hepatitis B virus core antigen, and mutate cysteine residues at positions 48 and 107 into serine, so that the hepatitis B virus core antigen can self-assemble into a virus-like nanoparticle with strong stability. The virus-like nanoparticle is used as a carrier, a B cell epitope peptide (tight junction protein CLDN18.2) of a gastric cancer tumor-related antigen is inserted into an immunodominant site of the carrier, so that the humoral immune response against gastric cancer is enhanced. Two T cell epitope peptides of the heterologous hepatitis B virus core antigen are used to replace T cell epitope peptides on the carrier, so that the cellular immune response against gastric cancer is enhanced, and strong antitumor effect and immune memory effect are shown.

An immunomodulatory nanoparticle vaccine carrier protein and its application. This invention uses duck hepatitis B virus core antigen (DHBc) as a base, fuses and expresses the SpyCatcher003 sequence to construct DHBc-SpyCatcher (DHBc-SC) virus-like particles with self-assembly capability, and efficiently expresses them in *E. coli*. When DHBc-SC virus-like particles are mixed with heterologous monomeric antigens containing SpyTag, they can spontaneously couple to form virus-like particles displaying the heterologous antigen, significantly enhancing the immunogenicity of the heterologous antigen.